(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-ethyloxolan-3-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-ethyloxolan-3-ol
• 化学式: C₁₁H₁₄ClN₅O₂
• 分子量: 283.71
• InChiKey: LMMOTBVCCYRRBE-RRKCRQDMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  99.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Chen Lijing

  公开号：US20180072742A1

  公开（公告）日：2018-03-15

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  该发明涉及新颖的杂环化合物及其药物制剂。该发明还涉及使用该新颖杂环化合物治疗或预防癌症的方法。
• NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES
  申请人：Patel Hasmukh B.

  公开号：US20160137685A1

  公开（公告）日：2016-05-19

  The invention provides phosphoramidate prodrugs for targeting and treating liver disease, including liver cancer, hepatocellular carcinoma, and hepatitis.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE AND CHRONIC METABOLIC DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET MÉTABOLIQUES CHRONIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014087323A2

  公开（公告）日：2014-06-12

  The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of autoimmune and chronic metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases, metabolic diseases, chronic kidney disease and autoimmune diseases.
• [EN] NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES<br/>[FR] NUCLÉOSIDE PHOSPHORAMIDATES ET PHOSPHORAMIDITES
  申请人：PATEL HASMUKH B

  公开号：WO2015013352A2

  公开（公告）日：2015-01-29

  The invention provides phosphoramidate prodrugs for targeting and treating liver disease, including liver cancer, hepatocellular carcinoma, and hepatitis.